Expression of WT1 gene in multiple myeloma patients at diagnosis: is WT1 gene expression a useful marker in multiple myeloma?

Basit Öğe Kaydı
dc.authoridKaynar, Leylagul/0000-0002-2035-9462
dc.authoridCETIN, Mustafa/0000-0003-4512-1124
dc.authoridCaglayan, Ahmet Okay/0000-0002-2332-322X
dc.authoridKOCYIGIT, ISMAIL/0000-0002-6654-4727
dc.authoridAltuntas, Fevzi/0000-0001-6872-3780
dc.authorwosidKaynar, Leylagul/F-6991-2013
dc.authorwosidAkalın, Hilal/AAD-2753-2022
dc.authorwosidCETIN, Mustafa/B-3607-2015
dc.authorwosidCaglayan, Ahmet Okay/D-1066-2012
dc.authorwosidOzkul, Yusuf/AAT-3574-2021
dc.authorwosidAltuntas, Fevzi/E-8945-2015
dc.contributor.authorSaatci, Cetin
dc.contributor.authorCaglayan, A. Okay
dc.contributor.authorKocyigit, Ismail
dc.contributor.authorAkalin, Hilal
dc.contributor.authorKaynar, Leyla G.
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorEser, Bulent
dc.date.accessioned2024-06-12T11:01:37Z
dc.date.available2024-06-12T11:01:37Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMonitoring patients with multiple myeloma during and after treatment for the presence of residual myeloma cells (minimal residual disease - MRD) has been shown to give a major insight into the effectiveness of treatment. It has been reported that Wilms' tumor gene (WT1) expression levels measured by real-time quantitative polymerase chain reaction was useful as an indicator of minimal residual disease in leukemia and myelodysplastic syndrome. The aim of this study was to measure levels of WT1 expression, in order to find a possible association between the expression of this gene and multiple myeloma at diagnosis. If an association was found, the WT1 gene could be evaluated as an MRD marker by comparison with other prognostic factors. We investigated peripheral blood WT1 expression level measured by real-time light cycler quantitative polymerase chain reaction in 50 newly diagnosed multiple myeloma patients. The normal WT1 gene copy number was found to be <23/mu l cDNA and all patients with myeloma were found to have normal WT1-mRNA levels. On this basis WT1 expression analyses is unlikely to be a useful genetic marker for routine clinical use in multiple myeloma patients at diagnosis.en_US
dc.identifier.doi10.1179/102453310X12583347009496
dc.identifier.endpage42en_US
dc.identifier.issn1024-5332
dc.identifier.issn1607-8454
dc.identifier.issue1en_US
dc.identifier.pmid20132661en_US
dc.identifier.scopus2-s2.0-76749131616en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage39en_US
dc.identifier.urihttps://doi.org/10.1179/102453310X12583347009496
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20971
dc.identifier.volume15en_US
dc.identifier.wosWOS:000274358200007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofHematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectExpressionen_US
dc.subjectMultiple Myelomaen_US
dc.subjectWT1en_US
dc.subjectWilms-Tumor Geneen_US
dc.subjectMinimal-Residual-Diseaseen_US
dc.subjectStem-Cell Transplantationen_US
dc.subjectPrognostic-Factoren_US
dc.subjectHuman Leukemiasen_US
dc.subjectMessenger-Rnaen_US
dc.subjectBone-Marrowen_US
dc.subjectCytogeneticsen_US
dc.subjectBlooden_US
dc.subjectTranscriptsen_US
dc.titleExpression of WT1 gene in multiple myeloma patients at diagnosis: is WT1 gene expression a useful marker in multiple myeloma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu